TIMOTHY MAGAW - Juventas Therapeutics, a Cleveland-based clinical-stage company developing regenerative therapies for treatment of cardiovascular diseases, has secured $13.5 million in financing to support future clinical studies. Green Cross Holdings and POSCO Capital led a $7.5 million Series B-2 equity investment, which included participation from other new and existing investors. Also, Juventas locked down $6 million in debt financing through Oxford Finance LLC, and Juventas said it has the opportunity to
↧